Jefferies & Company commented on Medtronic MDT in a report released yesterday. In the report, Jefferies was mixed in its assessment of the company.
Jefferies writes, "Fiscal 4Q11 results repeated the now rote script at Medtronic: weak CRM and Spine results not fully offset by growth in other markets. Revenues, while slightly above projections, were up just 0.4% ex-FX and were down 1.3% organically. U.S. ICDs were particularly dismal with -14% underlying growth. Newer markets did contribute more than expected, but the trends in the core markets remain very difficult."
Jefferies currently has a Hold rating on Medtronic and a price target of $43. Shares of Medtronic closed at $40.88 on Tuesday, up from $40.35 at the opening bell.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in